K220193 is an FDA 510(k) clearance for the BD MAX Enteric Parasite Panel. This device is classified as a Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-based Assay System (Class II - Special Controls, product code PCH).
Submitted by Becton, Dickinson and Company (Sparks, US). The FDA issued a Cleared decision on August 19, 2022, 207 days after receiving the submission on January 24, 2022.
This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3990. A Gastrointestinal Pathogen Panel Multiplex Nucleic Acid Assay Is A Qualitative In Vitro Diagnostic Device Intended To Simultaneously Detect And Identify Multiple Gastrointestinal Microbial Nucleic Acids Extracted From Human Stool Specimens. The Detection And Identification Of A Specific Gastrointestinal Microbial Nucleic Acid From Individuals Exhibiting Signs And/or Symptoms Of Gastrointestinal Infection Aids In The Diagnosis Of Gastrointestinal Infection When Used In Conjunction With Clinical Evaluation And Other Laboratory Findings..